Hemophilia A – Talk Bio

Recent Developments in Medical Affairs Reputation and Hemophilia A Management in the US (2025)

3 weeks ago talkbio0Tagged Acquired (qualifier value), Centers for Disease Control and Prevention (U.S.), federal funding, gene therapy, Health Policy, Hemophilia A, Hemophilia A Pipeline, Hemophilia Treatment Centers, HRSA, Medical Affairs, Programs - Publication Format, public health policy, reputation, U.S.

Medical Affairs; Reputation; Hemophilia A; US; 2025; Gene Therapy; Public Health Policies; Hemophilia Treatment Centers; 340B Program; Federal Funding; Acquired Hemophilia A Pipeline; Healthcare Policy; CDC; HRSA

BioMarin Plans to Divest Hemophilia Gene Therapy Roctavian Amid Strategic Refocus

2 months ago talkbio0Tagged BioMarin, Divestment, gene therapy, Hemophilia A, out-licensing, portfolio strategy, Roctavian

BioMarin; Roctavian; hemophilia A; gene therapy; divestment; out-licensing; portfolio strategy; third quarter 2025; revenue challenge

Pfizer Terminates Development of Sangamo’s Hemophilia A Gene Therapy, Returning Full Rights to Sangamo

12 months ago talkbio0Tagged Fitelparvovec, gene therapy, Giroctocogene, Hemophilia A, Pfizer, Phase 3 AFFINE Trial

Pfizer, Sangamo Therapeutics, Hemophilia A, Gene Therapy, Giroctocogene Fitelparvovec, Phase 3 AFFINE Trial

Pfizer Terminates Hemophilia A Gene Therapy Partnership with Sangamo, Citing Commercial Viability Concerns

12 months ago talkbio0Tagged commercial, gene therapy, Hemophilia A, partnership termination, Pfizer, Viable

Pfizer, Sangamo Therapeutics, Hemophilia A, Gene Therapy, Commercial Viability, Partnership Termination

FDA Approves Alhemo: A Breakthrough Once-Daily Treatment for Hemophilia A and B with Inhibitors

1 year ago talkbio0Tagged Alhemo, Approved, concizumab, Hemophilia A, Hemophilia B, inhibitors, once-daily, Prophylactic treatment, subcutaneous, United States Food and Drug Administration

Alhemo, FDA approval, hemophilia A, hemophilia B, inhibitors, concizumab, once-daily treatment, subcutaneous injection, prophylactic treatment

Roche Discontinues Second Hemophilia A Gene Therapy Candidate Under Spark Amid Shift in Hematologic Portfolio

1 year ago talkbio0Tagged gene therapy, Hemlibra, Hemophilia A, Roche (company)

Roche, Spark Therapeutics, Hemophilia A, Gene Therapy, RG6358, SPK-8016, Hemlibra, SPK-8011

Novo Nordisk Invests $1.2 Billion in New Danish Production Facility for Rare Disease Therapies

1 year ago talkbio0Tagged Denmark, disease drugs, Facility (object), Hemophilia A, Investments, Nordisk, pharmaceutical manufacturing, production

Novo Nordisk, rare disease drugs, Denmark, production facility, investment, hemophilia, pharmaceutical manufacturing

Pfizer’s Breakthrough Hemophilia Drug Hympavzi Wins EU Approval

1 year ago talkbio0Tagged Approved, EU, Hemophilia A, Hemophilia B, HYMPAVZI, marstacimab, once-weekly, Pfizer, pre-filled auto-injector pen, Subcutaneous Treatment

Pfizer, Hympavzi, EU approval, hemophilia A, hemophilia B, marstacimab, once-weekly subcutaneous treatment, pre-filled auto-injector pen

Pfizer’s HYMPAVZI Receives FDA Approval for Hemophilia A and B Treatment

1 year ago talkbio0Tagged anti-TFPI, Approved, Hemophilia A, Hemophilia B, HYMPAVZI, marstacimab-hncq, Pfizer, Subcutaneous Treatment, United States Food and Drug Administration

HYMPAVZI, marstacimab-hncq, hemophilia A, hemophilia B, FDA approval, Pfizer, subcutaneous treatment, anti-TFPI inhibitor

Pfizer Secures Second FDA Approval for Hemophilia Treatment in Six Months

1 year ago talkbio0Tagged Approved, gene therapy, Hemophilia A, Hemophilia B, HYMPAVZI, Pfizer, United States Food and Drug Administration

Pfizer, FDA approval, Hemophilia, Gene Therapy, Hemophilia B, HYMPAVZI